Journal of Vaccine Research 2024, Vol.14, No.3, 107-119 http://medscipublisher.com/index.php/jvr 117 vaccine coverage and effectiveness, particularly among vulnerable populations. By continuing to invest in research and public health initiatives, we can work towards the ultimate goal of eliminating hepatitis B as a global health threat. The lessons learned from the successes and challenges of HBV vaccination programs will be invaluable in guiding future strategies to combat this and other infectious diseases. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Alavian S., Fallahian F., and Lankarani K., 2010, Implementing strategies for hepatitis B vaccination, Saudi Journal of Kidney Diseases and Transplantation, 21(1): 10-22. Buchmann P., Dembek C., Kuklick L., Jäger C., Tedjokusumo R., Freyend M., Drebber U., Janowicz Z., Melber K., and Protzer U., 2013, A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice, Vaccine, 31(8): 1197-203. https://doi.org/10.1016/j.vaccine.2012.12.074 PMid:23306359 Chen W., and Gluud C., 2005, Vaccines for preventing hepatitis B in health-care workers, The Cochrane Database of Systematic Reviews, (4): CD000100. https://doi.org/10.1002/14651858.CD000100.PUB3 Cova L., 2014, Advances and challenges in the development of therapeutic DNA vaccines against hepatitis B virus infection, Current Gene Therapy, 14(3): 149-160. https://doi.org/10.2174/1566523214666140509102644 PMid:24828255 Goldstein S., Zhou F., Hadler S., Bell B., Mast E., and Margolis H., 2005, A mathematical model to estimate global hepatitis B disease burden and vaccination impact, International Journal of Epidemiology, 34(6): 1329-1339. https://doi.org/10.1093/ije/dyi206 PMid:16249217 Gomes C., Wong R., and Gish R., 2019, Global perspective on hepatitis B virus infections in the era of effective vaccines, Clinics in Liver Disease, 23(3): 383-399. https://doi.org/10.1016/j.cld.2019.04.001 PMid:31266615 Hennig B.J., Fielding K., Broxholme J., Diatta M., Mendy M., Moore C., Pollard A., Rayco-Solon P., Sirugo G., Sande M., Waight P., Whittle H., Zaman S., Hill A., and Hall A.J., 2008, Host genetic factors and vaccine-induced immunity to hepatitis B Virus Infection, PLoS One, 3(3): e1898. https://doi.org/10.1371/journal.pone.0001898 PMid:18365030 PMCid:PMC2268746 Hutin Y., Desai S., and Bulterys M., 2018, Preventing hepatitis B virus infection: milestones and targets, Bulletin of the World Health Organization, 96: 443-443. https://doi.org/10.2471/BLT.18.215210 PMid:29962544 PMCid:PMC6022619 Hwang E., and Cheung R., 2012, Global epidemiology of hepatitis B virus (HBV) infection, North American Journal of Medicine and Science, 4: 7. https://doi.org/10.7156/V4I1P007 Jiang H., Wang S., Deng M., Li Y., Ling Z., Shao L., and Ruan B., 2017, Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis, Vaccine, 35(20): 2633-2641. https://doi.org/10.1016/j.vaccine.2017.03.080 PMid:28404358 Kao J., and Chen D., 2002, Global control of hepatitis B virus infection, The Lancet Infectious Diseases, 2(7): 395-403. https://doi.org/10.1016/S1473-3099(02)00315-8 PMid:12127351 Keating G., and Noble S., 2003, Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B, Drugs, 63(10): 1021-1051. Langley J., Vesikari T., Machluf N., Spaans J., Yassin-Rajkumar B., Anderson D., Popovic V., and Diaz-Mitoma F., 2020, 8. higher hepatitis B antibody titres induced in all adults vaccinated with a tri-antigenic hepatitis B (HBV) vaccine, compared to a mono-antigenic HBV vaccine: results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT), Open Forum Infectious Diseases, 7: S26-S27. https://doi.org/10.1093/ofid/ofaa439.053 Lavanchy D., 2005, Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention, Journal of Clinical Virology, 34(Suppl 1): S1-S3. https://doi.org/10.1016/S1386-6532(05)00384-7 PMid:16461208
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==